China's National Medical Products Administration granted drug registration approval for Sihuan Pharmaceutical (HKG:0460) subsidiary Huisheng Biopharmaceutical's Dapagliflozin tablets for the treatment of type 2 diabetes in adult patients.
The medication also passed China's consistency evaluation of quality and efficacy of generic drugs, according to a Wednesday filing with the Hong Kong Exchange.